These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34140647)

  • 1. The impact of pharmacogenetic testing in patients exposed to polypharmacy: a scoping review.
    Meaddough EL; Sarasua SM; Fasolino TK; Farrell CL
    Pharmacogenomics J; 2021 Aug; 21(4):409-422. PubMed ID: 34140647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of Pharmacogenetic Testing to Modeled Medication Change Recommendations in a Long-Term Care Population with Polypharmacy.
    Sugarman EA; Cullors A; Centeno J; Taylor D
    Drugs Aging; 2016 Dec; 33(12):929-936. PubMed ID: 27826798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial.
    Elliott LS; Henderson JC; Neradilek MB; Moyer NA; Ashcraft KC; Thirumaran RK
    PLoS One; 2017; 12(2):e0170905. PubMed ID: 28151991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of pharmacogenetic testing in children and adolescents with severe mental disorders.
    Blasco-Fontecilla H
    J Neural Transm (Vienna); 2019 Jan; 126(1):101-107. PubMed ID: 29626260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Utility of Pharmacogenetic Testing and a Clinical Decision Support Tool to Enhance the Identification of Drug Therapy Problems Through Medication Therapy Management in Polypharmacy Patients.
    Kim K; Magness JW; Nelson R; Baron V; Brixner DI
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1250-1259. PubMed ID: 30479202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic testing in psychiatric inpatients with polypharmacy is associated with decreased medication side effects but not via medication changes.
    Collins AR; Kung S; Ho JT; Wright JA; Dammen KC; Johnson EK; Lapid MI; Leung JG
    J Psychiatr Res; 2020 Jul; 126():105-111. PubMed ID: 32442780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) - study protocol for a pragmatic randomized controlled trial.
    Stingl JC; Kaumanns KL; Claus K; Lehmann ML; Kastenmüller K; Bleckwenn M; Hartmann G; Steffens M; Wirtz D; Leuchs AK; Benda N; Meier F; Schöffski O; Holdenrieder S; Coch C; Weckbecker K
    BMC Fam Pract; 2016 Apr; 17():49. PubMed ID: 27112273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication Optimization Using Pharmacogenomic Testing in a Complex Mental Health Population Prescribed Psychiatric Polypharmacy.
    Wood AE; Agrawal D; Deem AP; Dupper Knoper TL; Merino RF; Molzof HE; Maus LE; Kim F; Lodin Z; Lim S
    J Clin Pharmacol; 2022 Jul; 62(7):898-904. PubMed ID: 35075665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avoidable drug-gene conflicts and polypharmacy interactions in patients participating in a personalized medicine program.
    Reynolds KK; Pierce DL; Weitendorf F; Linder MW
    Per Med; 2017 May; 14(3):221-233. PubMed ID: 29767587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Falls: the adverse drug reaction of the elderly and the impact of pharmacogenetics.
    Just KS; Schneider KL; Schurig M; Stingl JC; Brockmöller J
    Pharmacogenomics; 2017 Aug; 18(13):1281-1297. PubMed ID: 28776468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users.
    Chanfreau-Coffinier C; Hull LE; Lynch JA; DuVall SL; Damrauer SM; Cunningham FE; Voight BF; Matheny ME; Oslin DW; Icardi MS; Tuteja S
    JAMA Netw Open; 2019 Jun; 2(6):e195345. PubMed ID: 31173123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interventions to improve the appropriate use of polypharmacy for older people.
    Rankin A; Cadogan CA; Patterson SM; Kerse N; Cardwell CR; Bradley MC; Ryan C; Hughes C
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD008165. PubMed ID: 30175841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic polymorphism as an independent risk factor for frequent hospitalizations in older adults with polypharmacy: a pilot study.
    Finkelstein J; Friedman C; Hripcsak G; Cabrera M
    Pharmgenomics Pers Med; 2016; 9():107-116. PubMed ID: 27789970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decision-support systems for managing polypharmacy in the elderly: A scoping review.
    Mouazer A; Tsopra R; Sedki K; Letord C; Lamy JB
    J Biomed Inform; 2022 Jun; 130():104074. PubMed ID: 35470079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?
    Solomon HV; Cates KW; Li KJ
    Psychiatry Res; 2019 Jan; 271():604-613. PubMed ID: 30554109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preferences for pharmacogenomic testing in polypharmacy patients: a discrete choice experiment.
    Chen C; Roberts MH; Raisch DW; Thompson TA; Bachyrycz A; Borrego ME
    Per Med; 2022 Nov; 19(6):535-548. PubMed ID: 36317592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy.
    Brixner D; Biltaji E; Bress A; Unni S; Ye X; Mamiya T; Ashcraft K; Biskupiak J
    J Med Econ; 2016; 19(3):213-28. PubMed ID: 26478982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of pharmacogenetics in clinical practice: problems and solutions.
    Baskys A
    J Neural Transm (Vienna); 2019 Jan; 126(1):109-113. PubMed ID: 29922908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deprescribing interventions and their impact on medication adherence in community-dwelling older adults with polypharmacy: a systematic review.
    Ulley J; Harrop D; Ali A; Alton S; Fowler Davis S
    BMC Geriatr; 2019 Jan; 19(1):15. PubMed ID: 30658576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.